Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration.
The pharmacokinetic properties of meropenem were investigated in nine critically ill patients treated by continuous venovenous hemofiltration (CVVH). All patients received one dose of 1 g of meropenem intravenously. High-flux polysulfone membranes were used as dialyzers. Meropenem levels were measured in plasma and ultrafiltrate by high-performance liquid chromatography. The total body clearance and elimination half-life were 143.7 +/- 18.6 ml/min and 2.46 +/- 0.41 h, respectively. The post- to prehemofiltration ratio of meropenem was 0.24 +/- 0.06. Peak plasma drug concentrations measured 60 min postinfusion were 28.1 +/- 2.7 microgram/ml, and trough levels after 6 h of CVVH were 6.6 +/- 1.5 microgram/ml. The calculated total daily meropenem requirement in these patients with acute renal failure and undergoing CVVH was 2,482 +/- 321 mg. Based on these data, we conclude that patients with severe infections who are undergoing CVVH can be treated effectively with 1 g of meropenem every 8 h.
Thalhammer
F
F
Department of Internal Medicine I, Division of Infectious Diseases, University of Vienna, A-1090 Vienna, Austria. florian.thalhammer@akhwien.ac.at
Schenk
P
P
Burgmann
H
H
El Menyawi
I
I
Hollenstein
U M
UM
Rosenkranz
A R
AR
Sunder-Plassmann
G
G
Breyer
S
S
Ratheiser
K
K
D000368:Aged; D005260:Female; D006440:Hemofiltration; D006801:Humans; D008297:Male; D000077731:Meropenem; D008875:Middle Aged; D013845:Thienamycins / Q000008:administration & dosage / Q000493:pharmacokinetics*
D013845:Thienamycins; D000077731:Meropenem